Skip to main content
. 2015 Nov 14;4:e07916. doi: 10.7554/eLife.07916

Table 1.

Donors included in the study.

DOI: http://dx.doi.org/10.7554/eLife.07916.008

All donors cHCV SVR HD
n=29 n=37 n=25
Male, n (%) 16 (55) 21 (57) 12 (48)
Age, years, median (IQR1-3) 48 (42-55) 48 (44-58) 38 (31-46)
IgG anti-CMV positive, n (%) 14 (48) 24 (51) 11 (44)
Cirrhosis, n (%) 5 (17) 8 (22) na
Treatment experienced, n (%) 18 (62) 37 (100) na
Treatment (n per type: 0/1/2/3) 11/12/6/0 0/26/10/1 na
Delay post-treatment, years, median (IQR1-3) 3.8 (3.4-4.2) 1.7 (0.9-3.2) na